CDTX stock forecast
Our latest prediction for Cidara Therapeutics Inc's stock price was made on the March 13, 2024 when the stock price was at 0.67$.
In the short term (2weeks), CDTX's stock price should underperform the market by -1.09%. During that period the price should oscillate between -13.31% and +7.01%.
In the medium term (3months), CDTX's stock price should outperform the market by 4.70%. During that period the price should oscillate between -31.83% and +19.19%.
Get email alertsCreate a solid portfolio with CDTX
About Cidara Therapeutics Inc
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.03$ per share.
The book value per share is 2.97$
Three months stock forecastMarch 13, 2024
Financials
Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -31M | - | -6M | -0.03 | - | - | 90M | 2.97 | - | - | - |